Compare AJANTA PHARMA with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA AUROBINDO PHARMA AJANTA PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 24.4 18.4 132.6% View Chart
P/BV x 6.8 4.0 170.2% View Chart
Dividend Yield % 0.5 0.3 196.6%  

Financials

 AJANTA PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
AUROBINDO PHARMA
Mar-19
AJANTA PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,422830 171.3%   
Low Rs898527 170.3%   
Sales per share (Unadj.) Rs233.5333.9 69.9%  
Earnings per share (Unadj.) Rs44.040.4 108.9%  
Cash flow per share (Unadj.) Rs52.251.8 100.8%  
Dividends per share (Unadj.) Rs9.002.50 360.0%  
Dividend yield (eoy) %0.80.4 210.6%  
Book value per share (Unadj.) Rs255.1237.1 107.6%  
Shares outstanding (eoy) m88.02585.91 15.0%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x5.02.0 244.4%   
Avg P/E ratio x26.416.8 156.9%  
P/CF ratio (eoy) x22.213.1 169.6%  
Price / Book Value ratio x4.52.9 158.9%  
Dividend payout %20.56.2 330.5%   
Avg Mkt Cap Rs m102,081397,569 25.7%   
No. of employees `0006.817.9 38.1%   
Total wages/salary Rs m4,30725,849 16.7%   
Avg. sales/employee Rs Th3,022.610,956.9 27.6%   
Avg. wages/employee Rs Th633.41,447.7 43.8%   
Avg. net profit/employee Rs Th569.11,324.3 43.0%   
INCOME DATA
Net Sales Rs m20,554195,636 10.5%  
Other income Rs m2111,553 13.6%   
Total revenues Rs m20,765197,189 10.5%   
Gross profit Rs m5,66439,519 14.3%  
Depreciation Rs m7216,680 10.8%   
Interest Rs m122,626 0.4%   
Profit before tax Rs m5,14331,767 16.2%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m1,2737,269 17.5%   
Profit after tax Rs m3,87023,645 16.4%  
Gross profit margin %27.620.2 136.4%  
Effective tax rate %24.822.9 108.2%   
Net profit margin %18.812.1 155.8%  
BALANCE SHEET DATA
Current assets Rs m11,812153,645 7.7%   
Current liabilities Rs m3,776120,429 3.1%   
Net working cap to sales %39.117.0 230.3%  
Current ratio x3.11.3 245.2%  
Inventory Days Days77135 57.2%  
Debtors Days Days8264 128.1%  
Net fixed assets Rs m14,398103,909 13.9%   
Share capital Rs m175586 29.9%   
"Free" reserves Rs m22,277138,322 16.1%   
Net worth Rs m22,452138,908 16.2%   
Long term debt Rs m71,800 0.4%   
Total assets Rs m26,962264,544 10.2%  
Interest coverage x444.313.1 3,392.6%   
Debt to equity ratio x00 2.3%  
Sales to assets ratio x0.80.7 103.1%   
Return on assets %14.49.9 145.0%  
Return on equity %17.217.0 101.3%  
Return on capital %23.023.8 96.3%  
Exports to sales %049.6 0.0%   
Imports to sales %018.8 0.0%   
Exports (fob) Rs mNA97,091 0.0%   
Imports (cif) Rs mNA36,741 0.0%   
Fx inflow Rs m10,68297,316 11.0%   
Fx outflow Rs m2,10240,589 5.2%   
Net fx Rs m8,58056,727 15.1%   
CASH FLOW
From Operations Rs m3,74816,220 23.1%  
From Investments Rs m-2,228-28,768 7.7%  
From Financial Activity Rs m-1,47519,191 -7.7%  
Net Cashflow Rs m456,656 0.7%  

Share Holding

Indian Promoters % 73.8 54.1 136.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 8.0 19.5%  
FIIs % 7.6 27.7 27.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.2 166.7%  
Shareholders   20,968 69,601 30.1%  
Pledged promoter(s) holding % 4.4 8.6 51.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   DISHMAN PHARMA  CADILA HEALTHCARE  VENUS REMEDIES  DR. DATSONS LABS  GLENMARK PHARMA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

A Critical Update on the Market(Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy(Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers(Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Apr 9, 2021 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS